167 related articles for article (PubMed ID: 28648553)
1. Escitalopram plasma levels and antidepressant response.
Florio V; Porcelli S; Saria A; Serretti A; Conca A
Eur Neuropsychopharmacol; 2017 Sep; 27(9):940-944. PubMed ID: 28648553
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
4. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
Li H; Li T; Li G; Luo J
Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
7. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
[TBL] [Abstract][Full Text] [Related]
8. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
Wade AG; Toumi I; Hemels ME
Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
10. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
[TBL] [Abstract][Full Text] [Related]
11. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
Kasper S; Ebert B; Larsen K; Tonnoir B
Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.
Lin KM; Chiu YF; Tsai IJ; Chen CH; Shen WW; Liu SC; Lu SC; Liu CY; Hsiao MC; Tang HS; Liu SI; Chang LH; Wu CS; Tsou HH; Tsai MH; Chen CY; Wang SM; Kuo HW; Hsu YT; Liu YL
Pharmacogenet Genomics; 2011 Apr; 21(4):163-70. PubMed ID: 20859246
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
16. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
Uher R; Tansey KE; Dew T; Maier W; Mors O; Hauser J; Dernovsek MZ; Henigsberg N; Souery D; Farmer A; McGuffin P
Am J Psychiatry; 2014 Dec; 171(12):1278-86. PubMed ID: 25017001
[TBL] [Abstract][Full Text] [Related]
17. Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression.
Xu Y; Wei H; Zhu Y; Zhu Y; Zhang N; Qin J; Zhu X; Yu M; Li Y
J Affect Disord; 2019 May; 250():307-312. PubMed ID: 30875673
[TBL] [Abstract][Full Text] [Related]
18. Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls.
Ng CG; Wong SK; Loh HS; Yee A
Clin Ter; 2014; 165(6):e384-90. PubMed ID: 25524191
[TBL] [Abstract][Full Text] [Related]
19. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
Papakostas GI; Larsen K
Eur Arch Psychiatry Clin Neurosci; 2011 Apr; 261(3):147-56. PubMed ID: 20859636
[TBL] [Abstract][Full Text] [Related]
20. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
